Skip to main content

2015 Press Releases

Keyword Search
2017 | 2016 | 2015
11/11/15WAVE Life Sciences Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2015-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a preclinical biopharmaceutical company using its proprietary chemistry platform to design, develop and commercialize a broad pipeline of first-in-class or best-in-class stereopure nucleic acid therapeutics candidates, today announced the pricing of its initial public offering of 6,375,000 ordinary shares at a price to the public of $16.00 per share. In addition, WA... 
Printer Friendly Version
08/18/15WAVE Life Sciences Raises $66 Million in Series B Financing
Genetic medicine company continues to expand breadth of potential therapeutic applications for novel stereopure synthetic chemistry platform to treat rare diseases Pipeline to span multiple modalities, including RNAi, antisense and exon- skipping, among others BOSTON, Mass., August 18, 2015 – WAVE Life Sciences, a genetic medicine company focused on advancing first-in-class stereopure nucleic acid therapies for patients impacted by rare diseases, today announced the completion of an oversubsc... 
Printer Friendly Version
06/08/15WAVE Life Sciences Expands Stereopure Synthetic Chemistry Platform Capabilities, Augments Patent Portfolio with Addition of Single-Stranded RNAi (ssRNAi)
Licenses co-exclusive rights from Max Planck Institute for Biophysical Chemistry to develop and commercialize ssRNAi therapeutics Advances overall strategy to address wide range rare genetic diseases utilizing RNAi, antisense, exon-skipping and other oligonucleotide modalities Cambridge, Mass.,Singapore– On June 8, 2015, WAVE Life Sciences, a preclinical biopharmaceutical company using its proprietary synthetic chemistry drug development platform to design, develop and commercialize a broad ... 
Printer Friendly Version
04/07/15WAVE Life Sciences Appoints Roberto Guerciolini, M.D., as Senior Vice President and Head of Early Development
BOSTON & OKINAWA, JAPAN–April 7, 2015–WAVE Life Sciences today announced that Roberto Guerciolini, M.D., has been appointed as Senior Vice President and Head of Early Development. He was most recently Vice President and Product General Manager at Shire and brings tremendous biopharmaceutical research and development experience from lead identification through clinical development across multiple therapeutic areas. Dr. Guerciolini will lead WAVE Life Sciences’ translational and early clinical... 
Printer Friendly Version
02/02/15WAVE Life Sciences Closes $18 Million Series A Financing to Advance Stereopure Nucleic Acid Therapeutics
BOSTON & OKINAWA, JAPAN–February 2, 2015–WAVE Life Sciences today announced that it closed an $18 million Series A financing, led by RA Capital Management, LLC and Kagoshima Shinsangyo Sosei Investment LP, joining founding investor SNBL Ltd. The proceeds will fund the advancement of the Company’s pipeline of stereopure nucleic acid therapeutics, including antisense and exon-skipping drug candidates, which are being developed to treat diseases across multiple therapeutic areas. WAVE is buildi... 
Printer Friendly Version